The role of GLP-1 analogues, including oral semaglutide, in the treatment of type 2 diabetes – based on clinical trial results and current guidelines

Piotr Gręblowski; Anna Łosiowska; Karolina Kłoda

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

6/2024
vol. 10

Send email

Copy url:

abstract:

The role of GLP-1 analogues, including oral semaglutide, in the treatment of type 2 diabetes – based on clinical trial results and current guidelines

Piotr Gręblowski

¹

,

Anna Łosiowska

¹

,

Karolina Kłoda

^{1, 2}

Polskie Towarzystwo Medycyny Rodzinnej
MEDFIT Karolina Kłoda, Szczecin

Online publish date: 2025/01/28

View full text Get citation

Guidelines of scientific societies indicate a key role of GLP-1 (glucagon-like peptide-1) analogues in the treatment of type 2 diabetes mellitus, especially in patients who are overweight, living with obesity, and are at increased cardiovascular risk. Although this group primarily includes drugs in the form of subcutaneous injection, there is also an oral formulation available. Oral semaglutide is an effective, non-invasive method of treating type 2 diabetes mellitus. This has been proven in numerous studies, in which the effectiveness of oral semaglutide in reducing glycated haemoglobin value in adult patients with type 2 diabetes mellitus, in whom previous therapy did not provide adequate control of the disease, was assessed. It has also been shown to be effective in terms of weight loss. Semaglutide can also be safely used in patients with renal failure, in whom it additionally shows a nephroprotective effect.

keywords:

The role of GLP-1 analogues, including oral semaglutide, in the treatment of type 2 diabetes – based on clinical trial results and current guidelines

Piotr Gręblowski 1 , Anna Łosiowska 1 , Karolina Kłoda 1, 2

type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonists, drug therapy

Piotr Gręblowski

¹

,

Anna Łosiowska

¹

,

Karolina Kłoda

^{1, 2}